Quest Spring 2014 : Page 1

A Publication of Dr. William J. Catalona Q uest Spring 2014 • Volume 22, Number 1 and the Urological Research Foundation test is recommended for use in men with a PSA in the range of 4-10 ng/ml. Typically, US physicians recommend that men with a PSA in this range have a biopsy. However, benign Advancements in research bring bright hope to patients. conditions can elevate the PSA, leading to about biopsies. The test also has been unnecessary biopsies. PHI is a non-shown to be helpful in monitoring invasive option for men with a PSA in patients in active surveillance this range. programs. PHI testing is already PHI measures three forms of PSA available to the public in Europe and ([-2]proPSA, free PSA and total PSA), Australia. then uses a For further formula to The Prostate Health Index information on the calculate a PHI test, see the test provides more accurate combined PSA following previous index to information that physicians Q UEST articles: determine a and patients need for better “Phi Stands for patient’s Prostate Health probability of decision-making. Index” in developing Summer/Fall 2012 –Dr. William J. Catalona prostate cancer. It and “Phi: FDA is a more specific Approves New Blood Test to Improve test than the PSA and has a predictive Prostate Cancer Detection” in Winter ability for cancer aggressiveness. This 2012. Both articles are available online provides additional information to help at www.drcatalona.com. physicians and patients make decisions ©Dan Oldfield Research Project Comes to Fruition Prostate Health Index Test Now Available I n February, Northwestern Memorial Hospital became the first hospital in the US to offer the Prostate Health Index (PHI) test to the public. The test will soon be available throughout the US, giving patients access to a better diagnostic screening tool for prostate cancer. PHI is a simple blood test that is nearly 3 times more accurate in detecting prostate cancer than the free/total PSA test. Dr. Catalona conducted several feasibility studies on the development of this blood test during the past 12 years. He also led the pivotal study that gained its approval by the US Food and Drug Administration (FDA). The PHI test advances the science of prostate cancer management. The T Northwestern Memorial Hospital is the first hospital in the US to offer the PHI test. he funds and energies of the URF are directed to research for the prevention, detection, treatment and cure of prostate cancer. Please support the URF in these important research efforts.

RESEARCH PROJECT COMES TO FRUITION

Prostate Health Index Test Now Available<br /> <br /> The Prostate Health Index test provides more accurate information that physicians and patients need for better decision-making.<br /> –Dr. William J. Catalona<br /> <br /> In February, Northwestern Memorial Hospital became the first hospital in the US to offer the Prostate Health Index (PHI) test to the public. The test will soon be available throughout the US, giving patients access to a better diagnostic screening tool for prostate cancer.<br /> <br /> PHI is a simple blood test that is nearly 3 times more accurate in detecting prostate cancer than the free/total PSA test. Dr. Catalona conducted several feasibility studies on the development of this blood test during the past 12 years. He also led the pivotal study that gained its approval by the US Food and Drug Administration (FDA).<br /> <br /> The PHI test advances the science of prostate cancer management. The test is recommended for use in men with a PSA in the range of 4-10 ng/ml. Typically, US physicians recommend that men with a PSA in this range have a biopsy. However, benign conditions can elevate the PSA, leading to unnecessary biopsies. PHI is a noninvasive option for men with a PSA in this range.<br /> <br /> PHI measures three forms of PSA ([-2]proPSA, free PSA and total PSA), then uses a formula to calculate a combined PSA index to determine a patient’s probability of developing prostate cancer. It is a more specific test than the PSA and has a predictive ability for cancer aggressiveness. This provides additional information to help physicians and patients make decisions about biopsies. The test also has been shown to be helpful in monitoring patients in active surveillance programs. PHI testing is already available to the public in Europe and Australia.<br /> <br /> For further information on the PHI test, see the following previous QUEST articles: “Phi Stands for Prostate Health Index” in Summer/Fall 2012 and “Phi: FDA Approves New Blood Test to Improve Prostate Cancer Detection” in Winter 2012. Both articles are available online at www.drcatalona.com.<br /> <br /> The funds and energies of the URF are directed to research for the prevention, detection, treatment and cure of prostate cancer. Please support the URF in these important research efforts.

Next Page


Publication List
Using a screen reader? Click Here